Intas And Arecor Ally On Value-Added Development
Accord To Market Reformulated Product Based On Arestat Proprietary Technology
Executive Summary
Intas and Arecor have struck an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop value-added medicines, in particular for use outside of the hospital setting.
You may also be interested in...
Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Study Offers Support For Biosimilar-To-Biosimilar Switching
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.
Cutting Through The Confusion On US Biosimilar Interchangeability
Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings.